270
Participants
Start Date
May 1, 2018
Primary Completion Date
April 19, 2022
Study Completion Date
April 19, 2022
Tenofovir Alafenamide
Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
Kaohsiung Medical University Hospital, Kaohsiung City
E-Da Hospital, Kaohsiung City
Stanford University Medical Center, Palo Alto
San Jose Gastroenterology, San Jose
Kyushu University Hospital, Fukuoka
Nagoya City University, Nagoya
Osaka City University, Osaka
Saga University Hospital, Saga
Hanyang University Seoul Hospital, Seoul
Nowon Eulji Medical Center, Eulji University College of Medicine,, Seoul
Sanggye Paik Hospital, Inje University College of Medicine, Seoul
China Medical University Hospital, Taichung
Collaborators (1)
Gilead Sciences
INDUSTRY
Stanford University
OTHER